ArticlePain and therapy2026
Beyond Nerve Hyperexcitability: Potential Implications of Cerebrospinal Fluid CASPR2 Antibodies for Central Pain Processing in Isaacs Syndrome: A Case-Based Systematic Review.
Article in Pain and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIsaacs syndrome (IS), or acquired neuromyotonia, is a rare immune-mediated neuromuscular disorder characterized by increased peripheral nerve excitability. Clinically, it manifests with fasciculations, cramps, excessive sweating, and the presence of CASPR2 autoantibodies in the serum. IS can occur as a paraneoplastic condition or may remain idiopathic.
methodsWe report an adult case of IS that prompted a case-based literature review investigating the association between cerebrospinal fluid (CSF) CASPR2 antibodies and IS. A systematic literature search of PubMed and Scopus was conducted on 7 July 2026, with reference-list screening of eligible articles for additional relevant studies. Eligible studies reported original data on adults with IS and CSF CASPR2 antibody testing; reviews, editorials, abstracts, letters, pediatric studies, and studies without relevant CSF testing were excluded. DISCUSSION: A 65-year-old man with a history of prostate cancer, treated with radiotherapy 4 years earlier, presented with a 3-year history of neuropathic pain and painful lower-limb cramps. Examination revealed fasciculations in all limbs and brisk tendon reflexes, with no Babinski sign. Neurophysiological studies demonstrated spontaneous doublet, triplet, and multiplet discharges. IS was supported by weakly positive serum VGKC-complex antibodies, low-positive LGI1 antibodies, and strongly positive CASPR2 antibodies, with strong CASPR2 positivity in cerebrospinal fluid, despite the absence of clinical features of Morvan syndrome. Our literature review identified six additional cases of IS in which CSF CASPR2 antibodies were tested. Of these, three had positive CSF CASPR2 antibody results. In two cases, IS remained idiopathic, whereas, in the third, it was associated with recurrent malignant thymoma. Including our patient, all reported cases of IS with CSF CASPR2 positivity presented with neuropathic pain.
conclusionIS should be considered in patients presenting with painful muscle cramps and electromyographic evidence of peripheral nerve hyperexcitability. The presence of CASPR2 antibodies in the CSF may be associated with neuropathic pain and could suggest involvement of pain pathway sensitization, potentially including central sensitization mechanisms.
Indexed as
Identifiers
42809178What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.